Display options
Cite
Balabashin D, Kovalenko E, Toporova V, et al. Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains. Cytotechnology. 2014;67(5):761-72doi: 10.1007/s10616-014-9714-3.
Balabashin, D., Kovalenko, E., Toporova, V., Aliev, T., Panina, A., Svirshchevskaya, E., Dolgikh, D., & Kirpichnikov, M. (2015). Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains. Cytotechnology, 67(5), 761-72. https://doi.org/10.1007/s10616-014-9714-3
Balabashin, Dmitriy, et al. "Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains." Cytotechnology vol. 67,5 (2015): 761-72. doi: https://doi.org/10.1007/s10616-014-9714-3
Balabashin D, Kovalenko E, Toporova V, Aliev T, Panina A, Svirshchevskaya E, Dolgikh D, Kirpichnikov M. Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains. Cytotechnology. 2015 Oct;67(5):761-72. doi: 10.1007/s10616-014-9714-3. Epub 2014 Jun 18. PMID: 24939591; PMCID: PMC4545435.
Copy Download .nbib Format: NLM
Share it on

Cytotechnology. 2015 Oct;67(5):761-72. doi: 10.1007/s10616-014-9714-3. Epub 2014 Jun 18.

Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains.

Cytotechnology

Dmitriy Balabashin, Elena Kovalenko, Viktoria Toporova, Teimur Aliev, Anna Panina, Elena Svirshchevskaya, Dmitry Dolgikh, Mikhail Kirpichnikov

Affiliations

  1. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, GSP-7, Miklukho-Maklaya, 16/10, 117997, Moscow, Russia, [email protected].

PMID: 24939591 PMCID: PMC4545435 DOI: 10.1007/s10616-014-9714-3

Abstract

Tumor necrosis factor-α (TNF-α) plays a key role in rheumatoid arthritis and some other autoimmune diseases. Therapy with anti-TNF-α recombinant antibodies (Ab) appears to be highly effective. Production of new hyper-producing eukaryotic cell lines can decrease the treatment cost, which currently is very high. However, due to the complexity of protein transcription, translation, processing, and secretion in mammalian cells, the stages at which antibody expression is affected are still poorly determined. The aim of this work was to compare the productivity of two cell lines developed in CHO DG44 cells, deficient in dihydrofolate reductase, transfected with vectors carrying either heavy (H) or light (L) chains of chimeric antibody under different combinations of selective elements. Both H and L chains were cloned either in pOptiVEC or pcDNA3.3 vectors and different combinations were used to produce HL and LH cell lines. We have shown that Ab production has been low and comparable between HL and LH cells until selection on methotrexate (MTX) when LH but not HL cells have responded with 3.5 times increased productivity. Flow cytometry analysis has demonstrated that intracellular concentration of full size Abs in LH cells was 5.6 times higher than in HL ones due to higher amount of H chain synthesis. No differences in viability between HL and LH cells have been found. We have concluded that the expression of H chain in the pOptiVEC vector, which is responsible for MTX resistance, has led to the suppression of H chain synthesis and limitation in full Ab assembly.

References

  1. Biotechnol Bioeng. 2001 May 20;73(4):261-70 - PubMed
  2. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 May;21(3):312-5, 318 - PubMed
  3. Biotechnol Bioeng. 2011 Feb;108(2):386-94 - PubMed
  4. Biochem Soc Trans. 1995 Feb;23(1):1-25 - PubMed
  5. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2197-9 - PubMed
  6. Biotechnol Prog. 2007 Mar-Apr;23(2):465-72 - PubMed
  7. Protein Eng Des Sel. 2009 Mar;22(3):169-74 - PubMed
  8. Biochemistry (Mosc). 2010 Dec;75(12):1458-63 - PubMed
  9. Appl Microbiol Biotechnol. 2004 Feb;63(5):527-36 - PubMed
  10. Russ J Immunol. 2002 Dec;7(4):371-4 - PubMed
  11. Biotechnol Prog. 2007 Jan-Feb;23(1):200-9 - PubMed
  12. Biotechnology (N Y). 1991 Jan;9(1):64-8 - PubMed
  13. Rheumatol Int. 2013 May;33(5):1351-3 - PubMed
  14. Biotechnol Prog. 2005 Jan-Feb;21(1):122-33 - PubMed
  15. Cytotechnology. 2011 May;63(3):247-58 - PubMed
  16. Biotechnology (N Y). 1990 May;8(5):421-7 - PubMed
  17. Biotechnol Prog. 2006 Jan-Feb;22(1):313-8 - PubMed
  18. J Immunol Methods. 1997 May 12;204(1):99-102 - PubMed
  19. Biotechnol Bioeng. 2009 Jan 1;102(1):188-99 - PubMed
  20. Annu Rev Biochem. 2005;74:739-89 - PubMed
  21. Eur J Biochem. 1989 May 15;181(3):545-53 - PubMed
  22. Curr Opin Biotechnol. 1995 Oct;6(5):553-60 - PubMed
  23. Gene. 1989 Apr 15;77(1):51-9 - PubMed
  24. Biotechnol Bioeng. 2012 Jan;109(1):125-36 - PubMed
  25. Enzyme Microb Technol. 1994 May;16(5):354-64 - PubMed
  26. Biotechnol Prog. 2005 Jan-Feb;21(1):148-53 - PubMed
  27. Biotechnol Bioeng. 1997 Sep 5;55(5):783-92 - PubMed
  28. Biotechnol Bioeng. 2000 Jan 5;67(1):97-103 - PubMed
  29. Indian J Pharmacol. 2011 Nov;43(6):724-5 - PubMed
  30. Biotechnol Prog. 2011 Nov-Dec;27(6):1689-99 - PubMed
  31. Biotechnol Bioeng. 2003 Nov 20;84(4):439-44 - PubMed

Publication Types